peptides. [2, 25] Platelets also have anti-inflammatory [26] and analgesic properties. [2, 18, [27] [28] [29] [30] PRP has been used since 1970s and they are becoming increasingly popular since then. There are various ways of preparing PRP in the market. Initially, simple centrifugation was used, and later many advances happened in many commercial systems. In newer systems, by adding collagen, calcium, thrombin, by glass contact or by freezing cycles, helps to activate platelets. Some systems use PRP as suspension, and some use it as gel. The technology is going through rapid growth in recent times. [31] [32] [33] The first use of Autologous PRP injections was reportedly in 1987 in open heart surgery. [34] The interest in PRP therapy grew intensely in last one decade, especially after 2009. In 2009, it was reported that two of the Pittsburgh Steelers received PRP for their ankle injuries before their triumph at the Super Bowl. [1] Due to the media attention, PRP became an accepted though unproven treatment for sports-related injuries. [35] 
IndIcatIons of Platelet-rIch Plasma
PRP is being used in various fields: [36, 39] The common indications [36] for which PRP is being used are: 1. Joint pains (chronic arthritis) 2. Chronic tendinopathies 3. Ligament sprains 4. Muscles strains 5. Intervertebral discs 6. Plantar fasciitis 7. Subacute and chronic sports injuries 8. Nerve injuries 9. Bone repair and regeneration 10. In plastic surgery 11. Oral surgery.
contraIndIcatIons
Absolute contraindications: [36] 1. Platelet dysfunction syndrome 2. Critical thrombocytopenia 3. Hemodynamic instability 4. Septicemia 5. Local infection at the site of the procedure 6. Patient unwilling to accept risks.
Relative contraindications: [36] 1. Consistent use of nonsteroidal anti-inflammatory drugs within 48 h of procedure 2. Corticosteroid injection at treatment site within 1 month 3. Systemic use of corticosteroids within 2 weeks 4. Tobacco use 5. Recent fever or illness 6. Cancer-especially hematopoietic or of bone 7. Hemoglobin (HGB) <10 g/dl 8. Platelet count <105/ul.
Why We need regeneratIve theraPIes lIke Platelet-rIch Plasma
The global impact of musculoskeletal conditions is huge and its continuously growing. [37] The World Health Organization has acknowledged that musculoskeletal injuries affect hundreds of millions of people worldwide and are the most common cause of severe long-term pain and physical disability. [38] Chronic and degenerative musculoskeletal conditions impose a great challenge to treat and can have major negative impact on an otherwise active lifestyle. Many of these patients might require a surgical intervention and follow-up rehabilitation program. Still, the outcome is not certain. There are very few treatments, which offer repair and healing the injuries. In view of these facts, the researches and case reports that suggest improvement in osteoarthritis (OA) symptoms and in other musculoskeletal injuries with PRP treatment generated huge interest in the PRP therapies for a wide variety of conditions. With more research, if proven effective, this would be a breakthrough nonoperative treatment option for many degenerative and variety of other conditions.
What Is Ideal Platelet-rIch Plasma?
PRP is basically a reversal of ratio between red blood cells and platelets. Red blood cells play minimal role in wound healing. In PRP, the red blood cells are reduced to <5% and platelet concentration is increased to more than 94%. Platelets are storehouse of number of powerful growth factors. In a healthy individual, a normal platelet count is between 150,000 and 450,000 cells/µl of blood. Platelet concentrations of <1000 × 106/ml were not reliable for enhancing wound healing. [1] The general consensus among most studies have suggested that effective concentration of platelet in PRP should be a minimum increase of 5 times the normal concentration of platelets (approximately 1 million platelets/μl). [1, 40] Concentration more than this has not shown any added benefits in wound healing. We do not know the ideal concentration and is yet to be defined.
Problems
We do not know: 1. What is the ideal concentration of PRP 2. Which technique is better as several techniques and commercial products are used for PRP preparation 3. Which PRP is better as each commercial technique leads to formation of different product. Each has different biology and efficacy.
PRP preparations (varieties): [ More than 40 commercial PRP systems are available [46] and each product may contain differing:
• Concentrations of platelets • Leukocytes, and • Growth factors.
groWth factors In Platelet-rIch Plasma
The important growth factors in PRP are 2, [41, 42] 1. Transforming growth factor-Β -stimulates undifferentiated mesenchymal cell proliferation, endothelial chemotaxis, and angiogenesis, inhibits macrophage and lymphocyte proliferation, regulates endothelial, fibroblastic, and osteoblastic mitogenesis, mitogenic effects of other growth factors, collagen synthesis, and collagenase secretion 2. Platelet-derived growth factors (PDGF-AB and PDGF-BB) -mitogenetic for mesenchymal cells and osteoblasts, stimulates chemotaxis and mitogenesis in fibroblast, glial, or smooth muscle cells, regulates collagenase secretion and collagen synthesis, stimulates macrophage and neutrophil chemotaxis 3. Insulin-like growth factor (IGF) improves the early healing of tendon defects by over-expression of IGF-1, [43] chemotactic for fibroblasts and stimulates protein synthesis, enhances bone formation 4. Vascular endothelial growth factors -stimulating new blood vessel formation to bring nutrients and progenitor cells to the injury site, stimulates mitogenesis for endothelial cells 5. Epidermal growth factor -stimulates endothelial chemotaxis or angiogenesis, regulates collagenase secretion, stimulates epithelial, or mesenchymal mitogenesis 6. Fibroblast growth factor-2 -stimulating new blood vessel formation to bring nutrients and progenitor cells to the injury site 7. Platelet factor 4 -stimulate the initial influx of neutrophils into wounds, chemoattractant for fibroblasts 8. Interleukin 8 -pro-inflammatory mediator, recruitment of inflammatory cells 9. Keratinocyte growth factor -promote endothelial cell growth, migration, adhesion and survival, angiogenesis.
hoW they helP
• Stabilize the damaged tissue during initial stages of tissue repair • Direct the local mesenchymal and epithelial cells to migrate, divide, and increase collagen and matrix synthesis • Ultimately leading to fibrous connective tissue and scar formation.
Platelet-rIch Plasma Procedure [44] PRP therapy has simple three steps: Variability in the intervention, as identified by the study authors, may bias the results (e.g., comparing preparations with high platelet concentrations versus those with low concentrations).
Overall, the evidence was considered low quality, given the uncertainty related to estimates of effect, according to the GRADE approach.
Of the 19 included trials, 11 did not provide a prior protocol or trial registration details for the study, which may bias results in favor of the intervention.
Cochrane review concludes that: 1. No benefit attributable to PRP for short-, medium-, or long-term function 2. Short-term improvements in pain were identified, but the effect sizes were small and unlikely to be clinically important.
Similar results were found in a paper published by Harris. [46] Sheth et al. [47] published a paper on the efficacy of autologous PRP use for orthopedic indications: a meta-analysis. They concluded that there is a lack of standardization of study protocols, platelet-separation techniques, and outcome measures. There is uncertainty about PRP use as a treatment modality for orthopedic bone and soft-tissue injuries.
Cole et al. [48] published a paper in Sports Health in May 2010. A PubMed search was performed for studies relating to PRP, growth factors, and soft tissue injuries from 1990 to 2010. There has been the widespread anecdotal use of PRP for muscle strains, tendinopathy, and ligament injuries and as a surgical adjuvant to rotator cuff repair, anterior cruciate ligament reconstruction, and meniscal or labral repairs. Although the fascination with this emerging technology has led to a dramatic increase in its use, scientific data supporting this use are still in their infancy. They concluded that despite the promising results of several animal studies, well-controlled human studies are lacking.
Fitzpatrick et al. [4] in 2016 published a meta-analysis of the outcomes of the PRP groups by preparation method and injection technique in tendinopathy. The aim was to determine the clinical effectiveness of the preparations and to evaluate the effect of controls used in the studies reviewed. They included a total of 18 studies, and 1066 participants. Out of that 8 studies were at low risk of bias. The study quality was assessed using Cochrane Collaboration risk-of-bias tool by 2 reviewers. The primary outcome was a change in pain intensity. They found that with the use of leukocyte-rich (LR) PRP, there was a strongly positive effect compared to leukocyte-poor PRP use. There was no significant difference in control groups whether they used saline, local anesthetic, steroid or dry needling. They concluded that there is good evidence to support the use of a single injection of LR-PRP under ultrasound guidance in tendinopathy. They also concluded that method of preparation and technique of injection is of great clinical significance.
Meheux et al. [49] did a systematic review to determine if PRP injection significantly improves outcomes in patients with symptomatic knee OA at 6 and 12 months posttreatment with PRP injection. They also did compare PRP and corticosteroid injections or viscosupplementation or placebo injections at 6 and 12 months post-PRP injection. In addition, they compared similarities and differences in outcomes based on the PRP formulations used in the different studies. They analyzed 6 studies, 739 patients, 817 knees, 39% males, mean age was 59.9 years; average follow-up was 38 weeks. They concluded that in symptomatic OA knee PRP injections results in clinical significant improvement up to 12 months post-PRP injection. PRP treatment is better and the difference, when compared to viscosupplementation, was found to be clinically significant.
Similar results were found by Kon et al. [50, 51] They also found that improvement ceases around 24 months and may need repeat PRP therapy.
Engebretsen et al. [52] in an IOC consensus paper on the use of PRP in sports medicine concluded that in the current scenario, it is advised to proceed with caution in the use of PRP in athletic sporting injuries.
conclusIon
PRP is very promising futuristic therapy. It is a vehicle to deliver large amount of important growth factors, which are biologically active, to the injury site. Its use has increased extensively over the last decade due to advanced technology, availability of newer commercial PRP equipment, manufacturing various PRP products in the market. It is very simple and easy to use, easily available, uses patient own blood (autologous), potential cost-effective, and considered very safe therapy. There are many case series showing positive outcomes. But despite the promising results of several animal studies, well-controlled human studies are lacking. The research is still in its infancy. There is no consensus or protocol for the use of PRP. Even with all the limited evidence available, today PRP is becoming a very popular therapy in various fields of medicine. More research in future will clear the clouds over many questions being raised about the efficacy and evidence for PRP. To conclude, we may say that there are reasonable amount of data which warrant continued research in PRP but currently its role in clinical practice is not completely defined.
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